Otonomy, Inc. (NASDAQ:OTIC) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07
|
Submission of Matters to a Vote of Security Holders. |
On June20, 2017, Otonomy, Inc. (the Company)
held its annual meeting of stockholders. Of the 30,256,999 shares
of common stock outstanding as of April26, 2017, the record date
for the meeting, 27,668,322 shares of common stock were
represented at the meeting in person or by proxy, constituting
91.44% of the outstanding common stock entitled to vote. The
matters voted upon at the meeting and the vote with respect to
each such matter are set forth below:
(1) |
Election of three ClassIII directors to hold office until the 2020 annual meeting of stockholders. Each of the following nominees was elected to serve as a ClassIII director, to hold office until the Companys 2020 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal. |
|
|
For |
Withheld |
BrokerNon-Votes |
|||||||||
|
|
23,418,233 | 2,857,652 | 1,392,437 | |||||||||
|
|
26,226,160 | 49,725 | 1,392,437 | |||||||||
|
|
22,097,126 | 4,178,759 | 1,392,437 |
(2) |
The ratification of the appointment of Ernst Young LLP as the Companys independent registered public accounting firm for the fiscal year ending December31, 2017. The appointment of Ernst Young LLP as the Companys independent registered public accounting firm for the fiscal year ending December31, 2017 was ratified based on the following results of voting: |
|
|
|
|
|
|||
|
|
7,220 | 34,741 |
About Otonomy, Inc. (NASDAQ:OTIC)
Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company has developed a technology referred to as sustained-exposure that is designed to deliver drug that is retained in the ear for an extended period of time following a local administration. Its product candidates include OTIPRIO, OTO-104 and OTO-311. The Company’s product candidate, OTIPRIO, is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery. Its product candidate, OTO-104, is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere’s disease and other inner ear conditions. The Company’s product candidate, OTO-311, is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus.
